Vintafolide
A water-soluble, folate-receptor-targeted conjugate of folate and the vinca alkaloid desacetylvinblastine monohydrazide (DAVLBH) with potential antineoplastic activity. The folate moiety of vintafolide binds to folic acid receptors on the tumor cell surface and the agent is internalized via folate receptor-mediated endocytosis, delivering the tubulin-binding DAVLBH moiety directly into the tumor cell; DAVLBH binding to tubulin results in the disruption of microtubule assembly-disassembly dynamics, cell cycle arrest, and tumor cell apoptosis. Folic acid receptors are frequently upregulated on the surfaces of many tumor cell types. DAVLBH is a derivative of the natural product vinblastine. [ ]
Term info
Vintafolide
- EC145
- Folate-Vinca Alkaloid Conjugate EC145
- VINTAFOLIDE
- Vintafolide
NCIT_C116978, NCIT_C63923, NCIT_C128784, NCIT_C116977, NCIT_C157711, NCIT_C157712
742092-03-1
C86H109N21O26S2
CTRP, FDA
Vintafolide
36O410ZD4I
http://purl.obolibrary.org/obo/NCIT_C17219
EC145
488470
488470
Vintafolide
Pharmacologic Substance, Organic Chemical
C1831870
C62525
Term relations
- Vinca-Domain Binding Agent
- Chemical_Or_Drug_Has_Mechanism_Of_Action some Microtubule Process
- Chemical_Or_Drug_Affects_Gene_Product some Tubulin
- Chemical_Or_Drug_Has_Physiologic_Effect some Positive Regulation of Apoptosis
- Chemical_Or_Drug_Has_Physiologic_Effect some Negative Regulation of Cell Cycle